2020 Trigeminal Neuralgia Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs

February 2020 | 51 pages | ID: 259D179EA494EN
VPAResearch

Abstracts

The 2020 Trigeminal Neuralgia pipeline report presents a comprehensive overview of the research and development of Trigeminal Neuralgia drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Two drugs in pre-clinical phase, three drugs in phase 1 and four drugs in phase 2

As of February 2020, the Trigeminal Neuralgia pipeline remains robust with 9 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Trigeminal Neuralgia treatment. Diverse types of targeted therapies are being explored through clinical trials including Calcitonin gene-related peptide (CGRP) receptor antagonists; canabinoid receptor agonist; Nav1.7 voltage-gated sodium channel inhibitors; Neuromuscular blocking agents; Acetylcholine inhibitors; Sodium channel antagonists.

The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Trigeminal Neuralgia drug development history, latest news, and other developments.

It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.

PUBLISHER EXPERTISE

VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.

SCOPE:

• The report scope comprises of both pre-clinical phase and clinical phase development drugs for Trigeminal Neuralgia development
• Trigeminal Neuralgia pipeline compounds and molecules under study by both large scale and small companies are included in the report
• Trigeminal Neuralgia pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
• Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
• Further, orphan drug status, fast track designation, different grants awarded and special status for Trigeminal Neuralgia pipeline candidates included
• Business overview and snapshot of all companies involved in Trigeminal Neuralgia pipeline are included
• Latest market and pipeline developments are provided in the report

Trigeminal Neuralgia (Tic Douloureux) pipeline companies included in the report are- Amgen Inc, Biogen Inc, Biohaven Pharmaceutical Holding Company Ltd, Grace Therapeutics LLC, InMed Pharmaceuticals Inc, Merz Pharma GmbH & Co KgaA, Noveome Biotherapeutics Inc, OliPass Corporation, PixarBio Corp

Trigeminal Neuralgia (Tic Douloureux) pipeline drugs profiled in the report include- erenumab (AMG-334), vixotrigine (CNV1014802), rimegepant, GTX-201, INM-405, incobotulinumtoxin A (Xeomin), ST266, OLP-1002, carbamazepine

Contents

1. TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2. EXECUTIVE SUMMARY

2.1 Report Scope and Research Methodology
2.2 Introduction to Trigeminal Neuralgia (Tic Douloureux) Condition
2.3 Trigeminal Neuralgia (Tic Douloureux) Pipeline Snapshot, 2020
2.4 Companies investing in Trigeminal Neuralgia (Tic Douloureux) pipeline therapeutics
2.5 Phase wise Trigeminal Neuralgia (Tic Douloureux) Pipeline Candidates
2.6 Most Researched Mechanism of Action of Trigeminal Neuralgia (Tic Douloureux) Pipeline Products
2.7 Route of Administration of Trigeminal Neuralgia (Tic Douloureux) Pipeline Drugs

3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT

3.1 Amgen Inc Overview, Contacts and ASD Pipeline Drugs
3.2 Biogen Inc Overview, Contacts and ASD Pipeline Drugs
3.3 Biohaven Pharmaceutical Holding Company Ltd Overview, Contacts and ASD Pipeline Drugs
3.4 Grace Therapeutics LLC Overview, Contacts and ASD Pipeline Drugs
3.5 InMed Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.6 Merz Pharma GmbH & Co KgaA Overview, Contacts and ASD Pipeline Drugs
3.7 Noveome Biotherapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.8 OliPass Corporation Overview, Contacts and ASD Pipeline Drugs
3.9 PixarBio Corp Overview, Contacts and ASD Pipeline Drugs

4. ACTIVE PIPELINE DRUG DETAILS, 2020

4.1 erenumab (AMG-334) Drug Details
  4.1.1 erenumab (AMG-334) Current Status
  4.1.2 erenumab (AMG-334) Drug Overview
  4.1.3 erenumab (AMG-334) Mechanism of Action
  4.1.4 erenumab (AMG-334) Licensing/Collaboration Companies
  4.1.5 erenumab (AMG-334) Clinical Trials
4.2 vixotrigine (CNV1014802) Drug Details
  4.2.1 vixotrigine (CNV1014802) Current Status
  4.2.2 vixotrigine (CNV1014802) Drug Overview
  4.2.3 vixotrigine (CNV1014802) Mechanism of Action
  4.2.4 vixotrigine (CNV1014802) Licensing/Collaboration Companies
  4.2.5 vixotrigine (CNV1014802) Clinical Trials
4.3 rimegepant Drug Details
  4.3.1 rimegepant Current Status
  4.3.2 rimegepant Drug Overview
  4.3.3 rimegepant Mechanism of Action
  4.3.4 rimegepant Licensing/Collaboration Companies
  4.3.5 rimegepant Clinical Trials
4.4 GTX-201 Drug Details
  4.4.1 GTX-201 Current Status
  4.4.2 GTX-201 Drug Overview
  4.4.3 GTX-201 Mechanism of Action
  4.4.4 GTX-201 Licensing/Collaboration Companies
  4.4.5 GTX-201 Clinical Trials
4.5 INM-405 Drug Details
  4.5.1 INM-405 Current Status
  4.5.2 INM-405 Drug Overview
  4.5.3 INM-405 Mechanism of Action
  4.5.4 INM-405 Licensing/Collaboration Companies
  4.5.5 INM-405 Clinical Trials
4.6 incobotulinumtoxin A (Xeomin) Drug Details
  4.6.1 incobotulinumtoxin A (Xeomin) Current Status
  4.6.2 incobotulinumtoxin A (Xeomin) Drug Overview
  4.6.3 incobotulinumtoxin A (Xeomin) Mechanism of Action
  4.6.4 incobotulinumtoxin A (Xeomin) Licensing/Collaboration Companies
  4.6.5 incobotulinumtoxin A (Xeomin) Clinical Trials
4.7 ST266 Drug Details
  4.7.1 ST266 Current Status
  4.7.2 ST266 Drug Overview
  4.7.3 ST266 Mechanism of Action
  4.7.4 ST266 Licensing/Collaboration Companies
  4.7.5 ST266 Clinical Trials
4.8 OLP-1002 Drug Details
  4.8.1 OLP-1002 Current Status
  4.8.2 OLP-1002 Drug Overview
  4.8.3 OLP-1002 Mechanism of Action
  4.8.4 OLP-1002 Licensing/Collaboration Companies
  4.8.5 OLP-1002 Clinical Trials
4.9 carbamazepine Drug Details
  4.9.1 carbamazepine Current Status
  4.9.2 carbamazepine Drug Overview
  4.9.3 carbamazepine Mechanism of Action
  4.9.4 carbamazepine Licensing/Collaboration Companies
  4.9.5 carbamazepine Clinical Trials

5. LATEST TRIGEMINAL NEURALGIA (TIC DOULOUREUX) PIPELINE NEWS AND DEALS

6. APPENDIX

6.1 Our Databases and Reports
6.2 Research Methodolgy